An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Name: An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
License: Public Domain

Incyte Corporation

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

squamous-cell-carcinoma

squamous cell carcinoma of the anal canal, squamous cell carcinoma, anal cancer, retifanlimab, expanded access program, expanded access

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 848706
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.